Anxiety · anxiolyticSleep · circadianRussia-registered (Selank)
Calm & Sleep
Stack: Selank + DSIP · the calming, sleep-support side of the neuro category
"The down-regulation counterpart to the focus and neuroprotection stacks. Selank takes the edge off anxiety without sedation or dependence; DSIP is a much more speculative sleep-onset add. Honest framing: Selank has the better data, DSIP is the most experimental piece here, and neither is a UK-licensed medicine."
GoalAnxiety reduction / sleep quality
Compounds2 · Selank + DSIP
Human evidenceLimited–moderate — Russian clinical (Selank); DSIP mixed
StatusUK: unlicensed research chemicals — not controlled, legal to possess, but not approved medicines. Russia: Selank registered for anxiety; DSIP studied as Deltaran
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Registered use (Russia)
Selank
A registered anxiolytic medicine in Russia (developed at the Institute of Molecular Genetics), in clinical use for generalised anxiety since the 1990s.
DSIP
Studied in the former USSR as "Deltaran"; never a broadly registered pharmaceutical, and never licensed in the UK, US or EU.
Evidence it adds
Real-world Russian clinical exposure for Selank — far less for DSIP.
Basis: Russian pharmacology registration (Selank)
Research / trial evidence
Selank
Russian RCTs describe anxiolytic and mild nootropic effects without the sedation or dependence of benzodiazepines — modest sample sizes, limited Western replication.
DSIP
Older, inconsistent human data. DSIP does not reliably act as a hypnotic in controlled trials; its mechanism remains unresolved.
Evidence it adds
Moderate for Selank; weak and speculative for DSIP.
Basis: Russian clinical literature · limited Western RCTs
Grey-market / unsupervised use
Where / who
Both are sold as research peptides — Selank usually intranasal, DSIP reconstituted for subcutaneous use before sleep.
What changes
Product identity, purity and dose are unverified; the Russian safety record belongs to the registered product, not a grey-market vial.
Evidence it adds
None — this layer is about how unsupervised use diverges from the studied product.
Basis: real-world sourcing — not a trial tier
Regulatory — read carefully
MHRA (UK)
Neither is a licensed medicine and neither is a controlled drug — unlicensed research chemicals. "Legal to possess" is not "approved or safe".
Elsewhere
Selank is registered in Russia; DSIP has no broad approval anywhere. Not FDA/EMA-approved.
What it means
Low apparent toxicity, but thin evidence — especially for DSIP.
Basis: MHRA: unlicensed, not scheduled
Why this is the foundation
The neuro section already covers the up-regulation side — Semax-based focus stacks and neuroprotection. This pairing is the opposite direction: calming and sleep. Selank is the anchor — a Russia-registered anxiolytic with a real, if modest, clinical record, used for anxiety without the sedation or dependence of benzodiazepines. DSIP is the speculative add: a sleep-onset peptide whose human evidence is old and inconsistent. The honest framing: run Selank for the anxiety data it actually has, and treat DSIP as experimental — not a proven sleep aid.
Members only · the actionable depth
See exactly how it's run
Doses, titration structure and what to monitor are part of membership. The provenance, evidence and status above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Selank
intranasal, daily / as needed
DSIP
pre-sleep, nights needed
Selank is typically used intranasally through the day or before stressful events; DSIP before sleep on an as-needed basis. These mirror community and Russian-clinical patterns, not a prescription to follow.
What's worth monitoring
Both peptides have a low reported toxicity profile, and Selank in particular is noted for the absence of sedation, tolerance or dependence seen with conventional anxiolytics. The real caveats are evidential and practical: DSIP is the least proven piece and may simply not do much; and grey-market product identity and purity are unverified. Baseline sensibility and a clinician conversation are the floor. General information, not medical advice.
Pep IQ